Clinical Trials · NCT01169779

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

CompletedPhase 3Lixisenatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Sanofi
Enrollment
391
Start date
Jul 2010
Locations
35 sites, 4 countries
Primary endpoint
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
View Lixisenatide compound reference